Procter & Gamble Health Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Press Release for the quarter and year ended March 31, 2026".
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Limited reported strong Q4 FY2026 results with sales of ₹365 crores, up 20% year-over-year, and Profit After Tax (PAT) of ₹95 crores, up 55% YoY. For the full fiscal year (April 2025-March 2026), the company reported sales of ₹1385 crores (up 16%) and PAT of ₹327 crores (up 30%) compared to the comparable 12-month period last year. Note: The company changed its financial year from July-June to April-March, so comparisons are indexed against April 2024-March 2025. The Board has recommended a final dividend of ₹45 per share, bringing total dividend payout to ₹205 per share (including ₹160 interim dividend). Key products driving growth include Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
The company delivered robust double-digit growth in both revenue and profitability, with PAT growth significantly outpacing revenue growth indicating margin expansion. The strong dividend payout signals confidence in business performance and is positive for shareholder returns.